138 related articles for article (PubMed ID: 23321661)
1. Treatment of urinary retention caused by uterine leiomyoma with a gonadotropin-releasing hormone agonist: case report and review.
Chu CM; Dabney L; Hardart A
Female Pelvic Med Reconstr Surg; 2013; 19(1):52-5. PubMed ID: 23321661
[TBL] [Abstract][Full Text] [Related]
2. Beneficial effects of dienogest on uterine myoma volume: a retrospective controlled study comparing with gonadotropin-releasing hormone agonist.
Ichigo S; Takagi H; Matsunami K; Suzuki N; Imai A
Arch Gynecol Obstet; 2011 Sep; 284(3):667-70. PubMed ID: 21052701
[TBL] [Abstract][Full Text] [Related]
3. Effects of gonadotropin-releasing hormone agonists on uterine leiomyomas.
Cramer SF
Arch Pathol Lab Med; 1998 Dec; 122(12):1045-6. PubMed ID: 9870847
[No Abstract] [Full Text] [Related]
4. Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas.
Palomba S; Orio F; Russo T; Falbo A; Cascella T; Doldo P; Nappi C; Lombardi G; Mastrantonio P; Zullo F
Hum Reprod; 2004 Jun; 19(6):1308-14. PubMed ID: 15117890
[TBL] [Abstract][Full Text] [Related]
5. Effect of gonadotropin-releasing hormone agonist treatment upon angiogenesis in uterine leiomyoma.
Abulafia O; Kleinhaus K; Levi G; Lee YC; Sherer DM
Gynecol Obstet Invest; 2001; 52(2):108-13. PubMed ID: 11586038
[TBL] [Abstract][Full Text] [Related]
6. Acute urinary retention caused by a uterine leiomyoma: a case report.
Novi JM; Shaunik A; Mulvihill BH; Morgan MA
J Reprod Med; 2004 Feb; 49(2):131-2. PubMed ID: 15018444
[TBL] [Abstract][Full Text] [Related]
7. Medical treatment of uterocutaneous fistula with gonadotropin-releasing hormone agonist administration.
Seyhan A; Ata B; Sidal B; Urman B
Obstet Gynecol; 2008 Feb; 111(2 Pt 2):526-8. PubMed ID: 18239009
[TBL] [Abstract][Full Text] [Related]
8. Nulligravida with Large Uterine Leiomyoma: A Case Report.
Maharjan S; Thapa M; Pokhrel M
JNMA J Nepal Med Assoc; 2022 Jun; 60(250):577-580. PubMed ID: 35690986
[TBL] [Abstract][Full Text] [Related]
9. GnRH agonists before surgery for uterine leiomyomas. A review.
Crosignani PG; Vercellini P; Meschìa M; Oldani S; Bramante T
J Reprod Med; 1996 Jun; 41(6):415-21. PubMed ID: 8799917
[TBL] [Abstract][Full Text] [Related]
10. Urinary retention and voiding dysfunction in women with uterine leiomyoma: a case series.
Yazdany T; Bhatia NN; Nguyen JN
J Reprod Med; 2012; 57(9-10):384-9. PubMed ID: 23091984
[TBL] [Abstract][Full Text] [Related]
11. Cellular leiomyoma mimicking endometrial stromal neoplasm in association with GnRH agonist goserelin.
McCluggage WG; Bharucha H
Histopathology; 1999 Feb; 34(2):184-6. PubMed ID: 10064405
[No Abstract] [Full Text] [Related]
12. Changes in insulin sensitivity during GnRH agonist treatment in premenopausal women with leiomyoma.
Matsui S; Yasui T; Tani A; Kunimi K; Uemura H; Yamamoto S; Kuwahara A; Matsuzaki T; Tsuchiya N; Yuzurihara M; Kase Y; Irahara M
Clin Chim Acta; 2012 Jun; 413(11-12):960-5. PubMed ID: 22366120
[TBL] [Abstract][Full Text] [Related]
13. Use of a gonadotropin-releasing hormone agonist to manage perimenopausal women with symptomatic uterine myomas.
Wang PH; Lee WL; Cheng MH; Yen MS; Chao KC; Chao HT
Taiwan J Obstet Gynecol; 2009 Jun; 48(2):133-7. PubMed ID: 19574174
[TBL] [Abstract][Full Text] [Related]
14. [Three cases of urinary retention caused by uterine leiomyoma].
Kuroda K; Gotoh M; Okamura K; Ono Y; Ohshima S; Watanabe H; Odani K
Hinyokika Kiyo; 1999 Feb; 45(2):115-7. PubMed ID: 10212785
[TBL] [Abstract][Full Text] [Related]
15. Ultrasound guided high-intensity focused ultrasound combined with gonadotropin releasing hormone analogue (GnRHa) ablating uterine leiomyoma with homogeneous hyperintensity on T
Yang S; Kong F; Hou R; Rong F; Ma N; Li S; Yang J
Br J Radiol; 2017 May; 90(1073):20160760. PubMed ID: 28256923
[TBL] [Abstract][Full Text] [Related]
16. Effect of steroid add-back therapy on the proliferative activity of uterine leiomyoma cells under gonadotropin-releasing hormone agonist therapy.
Mizutani T; Sugihara A; Honma H; Komura H; Nakamuro K; Terada N
Gynecol Endocrinol; 2005 Feb; 20(2):80-3. PubMed ID: 15823826
[TBL] [Abstract][Full Text] [Related]
17. Oestrogen deficiency causes DNA damage in uterine leiomyoma cells: a possible mechanism for shrinkage of fibroids by GnRH agonists.
Cheng YM; Chou CY; Huang SC; Lin HC
BJOG; 2001 Jan; 108(1):95-102. PubMed ID: 11213012
[TBL] [Abstract][Full Text] [Related]
18. Uterine leiomyomata and sterility: therapy with gonadotropin-releasing hormone agonists and leiomyomectomy.
Kuhlmann M; Gärtner A; Schindler EM; Regidor PA; Bühler K; Schindler AE
Gynecol Endocrinol; 1997 Jun; 11(3):169-74. PubMed ID: 9209897
[TBL] [Abstract][Full Text] [Related]
19. Gonadotropin-releasing hormone agonist use before hysterectomy.
Stovall TG; Summit RL; Washburn SA; Ling FW
Am J Obstet Gynecol; 1994 Jun; 170(6):1744-8; discussion 1748-51. PubMed ID: 8203435
[TBL] [Abstract][Full Text] [Related]
20. Uterine fibroid embolization for patients with acute urinary retention.
Haskal ZJ; Armijo-Medina H
J Vasc Interv Radiol; 2008 Oct; 19(10):1503-5. PubMed ID: 18662887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
